CClinicalTrials.gg
Active, not recruitingNCT07216677Updated Oct 15, 2025

A Real-World Study of Interventional Clinical Outcomes in Patients With Open Angle Glaucoma and Other Chronic Eye Diseases

An observational study in Glaucoma, AMD and Diabetic Retinopathy (DR), sponsored by Interstat LLC. Active, not recruiting at 1 site in United States. Open to participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2025-10-15.

Sponsored by Interstat LLC · Observational

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
300
Ages
18 Years to 99 Years
Sex
All
01

Study summary

This is a real world investigation of patient who have undergone treatments for chronic eye conditions such as glaucoma and AMD.

Read the detailed description

The objective of the study is to understand the real-world outcomes after chronic disease treatments for glaucoma and AMD and to compare to reported clinical study outcomes

02

Conditions studied

  • Glaucoma
  • AMD
  • Diabetic Retinopathy (DR)

Keywords

  • Glaucoma AMD
03

In context

Glaucoma

1,818 studies on the registry are indexed under Glaucoma; 231 are open to participants now.

This study's planned enrollment of 300 is above the median of 103 across 454 observational studies indexed under Glaucoma.

Browse Glaucoma studies →

Lead sponsor

This is the only study on the registry with Interstat LLC as lead sponsor.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 99 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients with a chronic eye disease

Inclusion criteria

Clinical diagnosis of Glaucoma or AMD or Diabetic Retinopathy Recent history of a chronic disease intervention in the prior 6 months

Exclusion criteria

Exclusion Criteria:

Patient who are pregnant lactating younger than 18 years of age unable to execute informed consent.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
300 participants (estimated)
Patient registry
No

Groups and cohorts

  • Post-intervention Observational Group

    Other: Chronic Disease Intervention CDI

Interventions

  • OtherChronic Disease Intervention CDI

    Intervention for the management of a chronic eye disease

06

What researchers measure

Primary outcomes

  1. Changes in Chronic Disease Interventional outcomes such as Intraocular pressure, best corrected vision and other parameters.

    Longitudinal change in interventional chronic disease outcomes

    Time frame: up to 12 months

07

Study locations

1 site
  • Interstat
    White Plains, New York 10602, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Oct 15, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07216677
Lead sponsor
Interstat LLC
Responsible party
Tsontcho Ianchulev (Ophthalmologist, Interstat LLC) — Principal investigator
First posted
Oct 14, 2025
Start date
Oct 10, 2024
Primary completion
Oct 25, 2027 (estimated)
Completion
Oct 25, 2027 (estimated)
Last update
Oct 15, 2025

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion